Clinical Trial Update: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies [Phase 2]

View source ↗

Summary

Phase II study of Folotyn with leucovorin to prevent or reduce mucositis in patients with relapsed or refractory peripheral T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Folotyn (pralatrexate)

Snippet

Sponsor: Acrotech Biopharma Inc. | Conditions: Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 2 | Status: COMPLETED